www.alk.net
  • Patients
    • What is allergy
      • House dust mite allergy
      •  
      • Pollen allergy
      •  
      • Living with allergy
      •  
      • Socio-economic impact
      •  
    •  
    • What is allergic asthma
    •  
    • How is allergy diagnosed
    •  
    • Treating allergy
    •  
  •  
  • Healthcare Professionals
    • Treating allergy and asthma
    •  
    • Products
    •  
    • Adverse reactions
    •  
    • Initiation of treatment
    •  
    • Clinical trials
    •  
  •  
  • R&D
    • R&D pipeline
    •  
    • Understanding immunotherapy
    •  
    • Research
    •  
    • Congress activities
    •  
    • Clinical data sharing
    •  
  •  
  • Careers
    • Working at ALK
    •  
    • Vacant positions
    •  
  •  
  • Investors
    • Overview
    •  
    • Financial reporting
      • Risk management
      •  
      • Reporting standards
      •  
      • Auditors
      •  
    •  
    • Governance
      • IR policy
      •  
      • Management
      •  
      • Board of directors
      •  
      • Annual general meeting
      •  
      • Annual general meeting (DK)
      •  
    •  
    • News & Events
      • Company Releases
      •  
      • Company releases (DK)
      •  
      • Webcasts & presentations
      •  
      • Investor calendar
      •  
    •  
    • The Share
      • Dividend history
      •  
      • Analyst coverage
      •  
      • Analyst estimates
      •  
      • Shareholder information
      •  
      • Authorizations
      •  
      • ADR Programme
      •  
    •  
    • Contact IR
    •  
    • Management
    •  
    • Board of directors
    •  
    • AGM
    •  
    • AGM (DK)
    •  
    • Nyheder
    •  
    • Nyheder (EN)
    •  
  •  
  • Media
  •  
  • About
    • ALK at a glance
    •  
    • CSR
    •  
    • Production
    •  
    • Global presence
    •  
    • Organisation
    •  
    • History
    •  
    • Values
    •  
    • Owners
    •  
  •  
  • Select country
  •  
Search

News release

Links: 
Company Releases
Company releases (DK)
Webcasts & presentations
Investor calendar

« Back

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

February 24, 2021

PDF Version

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) reports the following transactions:

1.Details of the person discharging managerial responsibility/
person closely associated
a)NameCarsten Hellmann
2.Reason for the notification
a)Position/statusPresident & CEO
b)Initial notification/
amendment
Initial notification
3.Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)NameALK-Abelló A/S
b)LEI529900SGCREUZCZ7P020
4.Details of the transaction(s): section to be repeated for
(i) each type of instrument: (ii) each type of transaction;
(iii) each date;
and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument

Identification code
Shares

DK0060027142
b)Nature of the transactionSale
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 43,608,569         17,068
d)Aggregated information

- Aggregated volume

- Price
 

17,068

DKK 43,608,569
e)Date of the transaction2021-02-23
f)Place of the transactionNasdaq Copenhagen


                                                                                        ALK-Abelló A/S


For further information please contact:
Investor Relations: Per Plotnikof, mobile +45 2261 2525

Attachment

  • FM_04_21UK_24022021
  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved